Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer
Mark Wong, Howard Gurney(Radboud University Nijmegen), Andrew J. McLachlan(The University of Sydney), Stephen P. Ackland(Mater Misericordiae Hospital), Christine L. Clarke(Memorial University of Newfoundland), E. Blair(The University of Sydney), Scott Evans(The University of Sydney), Rosemary L. Balleine(The University of Sydney), Graham J. Mann(Murdoch University), Madhu B. Garg(The University of Sydney), David Farlow(The University of Sydney), Laurent P. Rivory(The University of Sydney), Janelle M. Hoskins(University of North Carolina at Chapel Hill), Michael Collins(University College Cork)
Cited by 64
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
|The American Journal of Human Genetics|2018|1.2k